To investigate the responses in terms of body weight, glycemic control, metabolic control, and the side effects to acarbose add-on therapy in obese and non-obese type 2 diabetes patients with inadequately controlled by sulfonylureas and metformin. Materials and Methods: Forty obese (BMI≤ 27) and 80 sex- and age-matched non-obese patients with type 2 diabetes mellitus were enrolled in this 3-month, open-label, case-controlled trial for acarbose add-on therapy. Totally 111 (73 non-obese and 38 obese) patients completed 3-month acarbose add-on therapy. This study adopted a 2-center open-label parallel group design. After a 4-week run-in period, acarbose was added (ti-trated up to 100 mg t.i.d.) to the current sulfony-lureas and metformin combined therapy of sub-jects. Both obese patients (9.3±1.3% vs. 8.3±1.6%, p<0.0001) and non-obese patients (9.4±1.2% vs. 8.4±1.2%, p<0.0001) showed decreased HbA1c af-ter therapy. While obese patients showed a sig-nificant serum alanine aminotransferase (ALT) (61±26 vs. 49±18, p<0.0001) and triglyceride re-duction (242±127 vs. 187±71, p<0.01) after add-on therapy, non-obese patients did not. Neither obese (74.8±9.2 vs. 74.4±9.8 kg, N.S.) nor non-obese patients (61.9±7.9 vs. 61.6±7.7 kg, p=0.0579) show significant decrease in body weight. Conclusion: Both obese patients and non-obese patients showed decreased HbA1c after acarbose therapy. Obese patients had an additional bene-fit of a decrease in their previoulsly elevated ALT and triglyceride levels after acarbose ther-apy.

"/> To investigate the responses in terms of body weight, glycemic control, metabolic control, and the side effects to acarbose add-on therapy in obese and non-obese type 2 diabetes patients with inadequately controlled by sulfonylureas and metformin. Materials and Methods: Forty obese (BMI≤ 27) and 80 sex- and age-matched non-obese patients with type 2 diabetes mellitus were enrolled in this 3-month, open-label, case-controlled trial for acarbose add-on therapy. Totally 111 (73 non-obese and 38 obese) patients completed 3-month acarbose add-on therapy. This study adopted a 2-center open-label parallel group design. After a 4-week run-in period, acarbose was added (ti-trated up to 100 mg t.i.d.) to the current sulfony-lureas and metformin combined therapy of sub-jects. Both obese patients (9.3±1.3% vs. 8.3±1.6%, p<0.0001) and non-obese patients (9.4±1.2% vs. 8.4±1.2%, p<0.0001) showed decreased HbA1c af-ter therapy. While obese patients showed a sig-nificant serum alanine aminotransferase (ALT) (61±26 vs. 49±18, p<0.0001) and triglyceride re-duction (242±127 vs. 187±71, p<0.01) after add-on therapy, non-obese patients did not. Neither obese (74.8±9.2 vs. 74.4±9.8 kg, N.S.) nor non-obese patients (61.9±7.9 vs. 61.6±7.7 kg, p=0.0579) show significant decrease in body weight. Conclusion: Both obese patients and non-obese patients showed decreased HbA1c after acarbose therapy. Obese patients had an additional bene-fit of a decrease in their previoulsly elevated ALT and triglyceride levels after acarbose ther-apy.

"/>

Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus

AUTHORS

Chou Chien-Wen 1 , Ou Horng-Yih 2 , Hsiao Shu-Hwa 2 , Wu Ta-Jen 3

1 Division of Endocrinology and Metabolism, Chi-Mei Medical Center, Tainan

2 Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan

3 College of Medicine, National Cheng Kung University, *, Taiwan

Warning: No corresponding author defined!

How to Cite: Chien-Wen C, Horng-Yih O, Shu-Hwa H, Ta-Jen W. Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus, Int J Endocrinol Metab. Online ahead of Print ; 4(2):63-69.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 4 (2); 63-69
Article Type: Original Article
Received: April 17, 2005
Accepted: December 9, 2005
READ FULL TEXT

Abstract

To investigate the responses in terms of body weight, glycemic control, metabolic control, and the side effects to acarbose add-on therapy in obese and non-obese type 2 diabetes patients with inadequately controlled by sulfonylureas and metformin. Materials and Methods: Forty obese (BMI≤ 27) and 80 sex- and age-matched non-obese patients with type 2 diabetes mellitus were enrolled in this 3-month, open-label, case-controlled trial for acarbose add-on therapy. Totally 111 (73 non-obese and 38 obese) patients completed 3-month acarbose add-on therapy. This study adopted a 2-center open-label parallel group design. After a 4-week run-in period, acarbose was added (ti-trated up to 100 mg t.i.d.) to the current sulfony-lureas and metformin combined therapy of sub-jects. Both obese patients (9.3±1.3% vs. 8.3±1.6%, p<0.0001) and non-obese patients (9.4±1.2% vs. 8.4±1.2%, p<0.0001) showed decreased HbA1c af-ter therapy. While obese patients showed a sig-nificant serum alanine aminotransferase (ALT) (61±26 vs. 49±18, p<0.0001) and triglyceride re-duction (242±127 vs. 187±71, p<0.01) after add-on therapy, non-obese patients did not. Neither obese (74.8±9.2 vs. 74.4±9.8 kg, N.S.) nor non-obese patients (61.9±7.9 vs. 61.6±7.7 kg, p=0.0579) show significant decrease in body weight. Conclusion: Both obese patients and non-obese patients showed decreased HbA1c after acarbose therapy. Obese patients had an additional bene-fit of a decrease in their previoulsly elevated ALT and triglyceride levels after acarbose ther-apy.

Full Text

Full text is available in PDF

© 0, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: